DBV Technologies cancels a presentation at a Goldman Sachs conference

DBV Technologies, a French biopharmaceutical company listed in Paris and on the Nasdaq, has announced changes to its participation in Goldman Sachs' 47th Annual Global Healthcare Conference. The event will be held on June 9, 2026, in Miami. Initially, DBV's management team was expected to participate actively. However, CEO Daniel Tassé will be unable to attend a planned informal discussion due to unforeseen circumstances.

The company focuses on treatments for food allergies. In particular, it is developing the VIASKIN® patch, which uses epicutaneous immunotherapy to desensitize patients to allergens. Despite this setback, DBV will maintain its investor meetings at the conference.